Investor Presentation - Female Testosterone for HSDD
Filed with ASX · · 26 pages · English
Summary by 6ix AI
Acrux Limited has released an investor presentation focused on Female Testosterone for Hypoactive Sexual Desire Disorder at the Bioshares Biotech Summit. The presentation outlines the company's expertise in transdermal drug delivery and its strategy to address women's health through hormone replacement therapies. It highlights the significant market opportunity for Female Testosterone, particularly among menopausal women affected by HSDD. The presentation also discusses the potential benefits of testosterone therapy for women's overall health and well-being.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Story so far
Earlier from Acrux
- Update - Licensing Lenzetto for Australia for AUD5.4m
- Acrux licenses Lenzetto for Australian market for AUD5.4m
- Capital Gains Tax exemptions remain in place for Acrux
- Acrux raises $1.6 million via Share Placement
- Australian company unlocks a new era for women's health globally with an innovative delivery system for Female testosterone in women with low libido
Later from Acrux
- FY26 Annual Report and Appendix 4E
- Acrux has received $1.977m RDTI rebate for FY26
- FDA clears regulatory pathway for Female Testosterone MDTS
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux